Biota is a leading anti-infective drug development company, based in Melbourne, Australia.
Biota's initial success was the discovery of zanamivir, the first-in-class neuraminidase inhibitor for the treatment and prevention of influenza. Zanamivir is licensed to GlaxoSmithKline and marketed as Relenza™. Relenza is used to treat seasonal influenza and is currently being stockpiled by various governments for defence against possible pandemic outbreaks of avian (bird) influenza.
Biota also has key partnerships with:
- Boehringer Ingelheim: where it has a licence and collaboration agreement to develop and commercialise Biota's novel nucleoside analogues, designed to treat hepatitis C virus (HCV) infections and potentially other diseases.
- MedImmune Inc: where it has a licence and collaboration agreement to develop Biota's lead compounds aimed at RSV (respiratory syncytial virus).
- Inverness Medical: Biota developed the influenza diagnostics OIA® FLU and OIA® FLU A/B influenza diagnostics, currently marketed as part of the BioStar® range.
- Daiichi-Sankyo: for the development of second generation influenza antivirals (called LANI or long-acting inhaled neuraminidase inhibitors).
In 2007, Biota completed a phase I clinical trial of its human rhinovirus (HRV) drug for the prevention and treatment of one of the major causes of the common cold which is also thought to be a major cause of exacerbations in patients with chronic obstructive pulmonary disease and asthma.
The Company's research pipeline also extends beyond respiratory diseases, including early stage research targeting the hepatitis C virus (HCV).